| dc.contributor.author | Yilmaz, Mehmet Birhan | |
| dc.contributor.author | Mebazaa, Alexandre | |
| dc.date.accessioned | 2019-07-27T12:10:23Z | |
| dc.date.accessioned | 2019-07-28T10:06:28Z | |
| dc.date.available | 2019-07-27T12:10:23Z | |
| dc.date.available | 2019-07-28T10:06:28Z | |
| dc.date.issued | 2011 | |
| dc.identifier.issn | 1466-609X | |
| dc.identifier.uri | https://dx.doi.org/10.1186/cc10308 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12418/9674 | |
| dc.description | WOS: 000298082800057 | en_US |
| dc.description | PubMed ID: 21892973 | en_US |
| dc.description.abstract | Levosimendan, in addition to its inotropic properties, could have anti-inflammatory and anti-oxidative properties, and can potentially decrease the deleterious effects of reactive oxygen species on the tissues. In their study, Hasslacher and colleagues provided not only in vitro but also in vivo evidence that levosimendan could preserve organ function in acute heart failure and septic-shock-induced myocardial depression via cooling down the oxidative burst of circulating cells. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | BIOMED CENTRAL LTD | en_US |
| dc.relation.isversionof | 10.1186/cc10308 | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care setting | en_US |
| dc.type | other | en_US |
| dc.relation.journal | CRITICAL CARE | en_US |
| dc.contributor.department | [Mebazaa, Alexandre] Univ Paris 07, Hosp Lariboisiere, APHP, INSERM,U942,Dept Anesthesiol & Crit Care Med, Paris, France -- [Yilmaz, Mehmet Birhan] Cumhuriyet Univ Sch Med, Dept Cardiol, Sivas, Turkey | en_US |
| dc.contributor.authorID | YILMAZ, MEHMET BIRHAN -- 0000-0002-8169-8628; YILMAZ, Mehmet Birhan -- 0000-0002-8169-8628; Mebazaa, Alexandre -- 0000-0001-8715-7753 | en_US |
| dc.identifier.volume | 15 | en_US |
| dc.identifier.issue | 4 | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
